Please assess the completion status of the following clinical trial:

Trial Title: Effect of Metabolic Control at Onset of Diabetes on Progression of Type 1 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 6.0 to \<46.0 years~* Diagnosis of type 1 diabetes with initiation of insulin therapy within past 7 days (day 1 being the first day of insulin therapy)~* If participant is female with reproductive potential, willing to avoid pregnancy and pregnancy test negative.~* Willing to accept randomization to either the intensive diabetes management group or the standard care group.~* Willing to complete the planned 2 years of follow-up.~* Able to electronically transmit data monthly.~* Investigator believes that the participant (and parent/guardian for children) understands and agrees to comply with the study protocol and is capable of undertaking all necessary testing.~Exclusion Criteria:~* Currently pregnant or lactating, or anticipate getting pregnant in the next one year.~* Currently anemic (hematocrit level will be obtained at the screening visit).~* Chronic use of systemic steroids or other noninsulin pharmaceuticals that might affect glycemic control or the presence of a disease that is likely to be treated with such medications during the first two years of the study.~* Complicating medical issues that might interfere with study conduct.~* Inpatient psychiatric treatment in the past 6 months (if the participant is a minor, for either the participant or the participant's primary care giver).~* Currently participating in another type 1 diabetes treatment study, including an intervention trial for treatment of diabetic ketoacidosis.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Intensive Treatment (Type: EXPERIMENTAL): closed loop therapy (4-6 days), insulin pump (2 years), continuous glucose monitoring (2 years), home glucose monitoring (2 years)
- Standard Treatment (Type: ACTIVE_COMPARATOR): home glucose monitoring (2 years)

Based on this trial design, predict the completion outcome and termination type (if applicable).